TECHNOLOGY | pHion Therapeutics

Phion technology

pH Responsive

Cationic

Helical

Conditional Cell Penetration

RALA is a 30 amino acid peptide with the following advantages for precision drug delivery:

Secondary

Amphipathic

RALA nanoparticles have many advantages

High cell transfection / cellular entry without associated toxicity

Self-assembly with nucleic cargo, irrespective of size

Stable nanoparticle with no need for cold chain storage

Non-immunogenic nanoparticles facilitate repeated dosing

Protection of drug cargo while increasing circulatory half-life

Demonstrated formulation lyophilisation and easy scale up

RALA : HOW DOES IT WORK?

RALA is optimised for both localised and systemic delivery, excelling in in vitro, in vivo and ex vivo applications.

FIND OUT MORE ABOUT RALA

PUBLICATIONS

Over 20+ studies have been published using the RALA system, ranging from the fundamental design and application of an efficient cell penetrating peptide to use as a potential therapeutic mRNA vaccine candidate.

Below is a selection of publications of special note:

McCarthy HO et al. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery.

J Control Release. 2014 Sep 10;189:141-9.

Udhayakumar VK et al. Arginine-Rich Peptide-Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide.

Adv Healthc Mater. 2017 Jul;6(13).

Ali AA et al. DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles.

Nanomedicine. 2017 Apr;13(3):921-932.

McCrudden CM et al. Systemic RALA/iNOS nanoparticles; a potent gene therapy for metastatic breast cancer coupled as a biomarker of treatment.

Mol Ther Nucleic Acids. 2017 Mar 17;6:249-258.

Cole G et al. Dissolving microneedles for DNA vaccination: improving functionality via polymer characterisation and RALA complexation.

Hum Vaccin Immunother. 2017 Jan 2;13(1):50-6.

Cole G et al. DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system.

Eur J Pharm Biopharm. 2018 Jun;127:288-297.

Cole G et al. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.

PHION TECHNOLOGY